Skip to main content
SpringerLink
Log in

How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer?

  • Chapter
  • First Online:
New Therapeutic Strategies in Lung Cancers

  • 1319 Accesses

Abstract

Disseminated micrometastatic disease often limits the effectiveness of aggressive locoregional treatment strategies in operable non-small cell lung cancer (NSCLC). The perioperative chemotherapy (neo- and adjuvant chemotherapy) results in a minimal survival advantage and is associated with a significant toxicity in a subgroup of patients. A proportion of early-stage patients are cured by local treatment modality alone and associated systemic treatment ends in a possible overtreatment, while in other patients, with the same pathological stage, systemic treatment is not effective at all. Therefore, there is a critical need to individualize systemic treatment in early-stage NSCLC. When treatment personalization is considered, two are the main goals: from one side, to reduce toxicity and, on the other, to improve efficacy outcomes. Currently new prospective trials for early stage are ongoing. In these studies patients are randomized to experimental treatment with cytotoxic or targeted agents that are customized by molecular pathways, genomic characterization, and/or immunological targets. Hopefully, awaited results from these trials will provide us new information for the management of stages I–III NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arriagada R, Dunant A, Pignon JP, et al. Long term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28:35–42.

    Article  PubMed  CAS  Google Scholar 

  2. Arriagada R, Auperin A, Burdett S, et al.; NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–77.

    Google Scholar 

  3. Arriagada R, Bergman B, Dunant A, et al.; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60.

    Google Scholar 

  4. Baillie R, Carlile J, Pendleton N, et al. Prognostic value of vascularity and vascular endothelial growth factor expression in non small cell lung cancer. J Clin Pathol. 2001;54:116–20.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non–small-cell lung cancer. J Clin Oncol. 2006;24:4731–7.

    Article  PubMed  CAS  Google Scholar 

  6. Bepler G, Olaussen KA, Vataire AL, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011;178:69–78.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bepler G, Sommers KE, Cantor A, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008;3:1112–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108:3713–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Burdett S, Stewart L, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611–21.

    Article  PubMed  Google Scholar 

  10. Butts CA, Socinski M, Mitchell P, et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol. 2013;31(No 15s): abstr 7500, 458s.

    Google Scholar 

  11. Capelletti M, Wang XF, Gu L, et al. Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. J Clin Oncol. 2010;28(No 15s): abstr 7008, 516s.

    Google Scholar 

  12. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006;107:1589–96.

    Article  PubMed  CAS  Google Scholar 

  13. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17(12):1818–25.

    Article  PubMed  CAS  Google Scholar 

  14. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004;2(2):E7.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Chen Q, Si Q, Xiao S, et al. Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol. 2013;30:353.

    Article  PubMed  Google Scholar 

  16. Cobo M, Massuti B, Moran T, et al. Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels. J Clin Oncol. 2008;26(No 15 Suppl): abstract 7533, 405s.

    Google Scholar 

  17. De Castro Jr G, Pasini FS, Siqueira SA, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep. 2011;25:693–9.

    Article  PubMed  Google Scholar 

  18. De Fraipont F, Levallet G, Creveuil C, et al. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin Cancer Res. 2012;18(10):2976–86.

    Article  PubMed  Google Scholar 

  19. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006;34:1416–26.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247–53.

    Article  PubMed  Google Scholar 

  21. Der SD, Sykes J, Pintilie M, et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol. 2014;9(1):59–64.

    PubMed  CAS  Google Scholar 

  22. Doll CM, Prystajecky M, Eliasziw M, et al. Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol. 2010;97:352–9.

    Article  PubMed  CAS  Google Scholar 

  23. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006;7(9):719–27.

    Article  PubMed  CAS  Google Scholar 

  24. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer. 2005;92:E25–30.

    PubMed  Google Scholar 

  25. Fairman JW, Wijerathna SR, Ahmad MF, et al. Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nat Struct Mol Biol. 2011;18:316–22.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28:3138–45.

    Article  PubMed  CAS  Google Scholar 

  27. Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol. 2007;25:2735–40.

    Article  PubMed  CAS  Google Scholar 

  28. Friboulet L, Olaussen KA, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368:1101–10.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Gandara DR, Grimminger PP, Mack PC, et al. Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: implications for therapy. J Clin Oncol. 2010;28(No 15s): abstr 7513, 541s.

    Google Scholar 

  30. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review. Lancet. 2007;369:1929–37.

    Article  PubMed  CAS  Google Scholar 

  31. Go H, Jeon YK, Park HJ, et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5:305–13.

    Article  PubMed  Google Scholar 

  32. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.

    Article  PubMed  Google Scholar 

  33. Goss GD, O’Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 Study. J Clin Oncol. 2013;31:3320–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  34. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 1997;17:S37–58.

    Article  PubMed  Google Scholar 

  35. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the P53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54(4855):4878.

    Google Scholar 

  36. Harada H, Miyamoto K, Yamashita Y, et al. Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer. Cancer. 2013;119(4):792–8.

    Article  PubMed  CAS  Google Scholar 

  37. Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating micro-RNA expression profiles in early stage non small cell lung cancer. Int J Cancer. 2012;130:1378–86.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  38. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  39. Hsu DS, Acharya CR, Balakumaran BS, et al. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A. 2009;106:5312–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  40. Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721–6.

    Article  PubMed  Google Scholar 

  41. Iwakiri S, Mino N, Takahashi T, et al. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I non small cell lung cancer. Cancer. 2009;115(11):2580–93.

    Article  PubMed  CAS  Google Scholar 

  42. Janjigian YY, Park BJ, Zakowski MF, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2011;6:569–75.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995;55:1407–12.

    PubMed  CAS  Google Scholar 

  44. Kamal NS, Soria JC, Mendiboure J, et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res. 2010;16:1206–15.

    Article  PubMed  CAS  Google Scholar 

  45. Kang CH, Jang BG, Kim DW, et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer. 2010;68(3):478–83.

    Article  PubMed  Google Scholar 

  46. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

    Article  PubMed  CAS  Google Scholar 

  47. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26:2450–6.

    Article  PubMed  CAS  Google Scholar 

  48. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009;115:5218–27.

    Article  PubMed  Google Scholar 

  49. Ko E, Kim Y, Park SE, et al. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer. Lung Cancer. 2012;77(2):401–6.

    Article  PubMed  Google Scholar 

  50. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009;4(1):22–9.

    Article  PubMed  Google Scholar 

  51. Lau CL, D’Amico DA, Harpole DH, et al. Clinical and molecular prognostic factors and models for non-small cell lung cancer. In: Lung cancer principles and practice. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 602–11.

    Google Scholar 

  52. Leichman CG, Lenz HJ, Leichman L, et al. Quantification of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15:3223–9.

    PubMed  CAS  Google Scholar 

  53. Li GF, Deng SJ, Weng WW, et al. ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(9):2131–3.

    PubMed  Google Scholar 

  54. Liao M, Wang H, Lin Z, et al. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33:125–32.

    Article  PubMed  CAS  Google Scholar 

  55. Lim E, Harris G, Patel A, et al. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009;4(11):1380–8.

    Article  PubMed  Google Scholar 

  56. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217–26.

    Article  PubMed  CAS  Google Scholar 

  57. Lokk K, Vooder T, Kolde R, et al. Methylation markers of early stage non-small cell lung cancer. PLoS One. 2012;7(6):e39813.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  58. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8(7):2286–91.

    PubMed  CAS  Google Scholar 

  59. Ludovini V, Flacco A, Bianconi F, et al. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemother Pharmacol. 2013;71(3):671–80.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  60. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I nonsmall cell lung cancer. PLoS Med. 2006;3:e467.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Marra A, Kemming D, Krueer T, et al. ERCC1 as a predictor of response to induction therapy for stage III non-small cell lung cancer. J Clin Oncol. 2013;31(15s): abstr 18511.

    Google Scholar 

  62. Maus MK, Mack PC, Astrow SH, et al. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013;8(5):582–6.

    PubMed  CAS  Google Scholar 

  63. NCCN Clinical practice guidelines in oncology. Non small cell lung cancer.V.1.2011. Accessed at http://www.nccn.org/professionals/physiciangls/PDF.nscl.pdf.

  64. NCT00373425 – Study of tarceva after surgery with or without adjuvant chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) patients who have Epidermal Growth Factor Receptor (EGFR) positive tumors (RADIANT) at www.clinicaltrials.gov.

  65. Neal JW, Pennell NA, Govindan R, et al. The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30: abstr 7010.

    Google Scholar 

  66. Novello S, Manegold C, Grohe C, et al. International tailored chemotherapy adjuvant trial: Itaca trial. J Clin Oncol. 2012;30(No 15s): abstr TPS7109.

    Google Scholar 

  67. Oxnard GR, Janjigian YY, Arcila ME, et al. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res. 2011;17:6322–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  68. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997;15:2858–65.

    PubMed  CAS  Google Scholar 

  69. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.

    Article  PubMed  Google Scholar 

  70. Pisters KM, Evans WK, Azzoli CG et al.; American Society of Clinical Oncology. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25(34):5506–18.

    Google Scholar 

  71. Pisters KMW, Vallieres E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non small- cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010;28:1843–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  72. Reiman T, Sève P, Vataire A, et al. Prognostic value of class III B-tubulin (Tubb3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): a validation study on three randomized trials. J Clin Oncol. 2008;26(15 Suppl): abstr 7506, 398s.

    Google Scholar 

  73. Rekhtman N, Azzoli CG, Kris MG, et al. Patterns of co-expression of ERCC1 and P27 in resected non-small cell lung cancer by immunohistochemistry. J Clin Oncol. 2008;26(15 Suppl): abstr 7595, 420s.

    Google Scholar 

  74. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009;27:5808–15.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  75. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One. 2009;4:e5133.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2:e1129.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2004;10(4):1318–25.

    Article  PubMed  CAS  Google Scholar 

  78. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res. 2004;10:4215s–9.

    Article  PubMed  CAS  Google Scholar 

  79. Rosell R, Camps C, Maestre J, et al. A randomized trial comparing preoperative plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–8.

    Article  PubMed  CAS  Google Scholar 

  80. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.

    Article  PubMed  CAS  Google Scholar 

  81. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253–63.

    Article  PubMed  CAS  Google Scholar 

  82. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172–8.

    Article  PubMed  CAS  Google Scholar 

  83. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Natl Cancer Inst. 2003;95(19):1453–61.

    Article  PubMed  CAS  Google Scholar 

  84. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of P53 and K-RAS mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol. 2001;19:448–57.

    PubMed  CAS  Google Scholar 

  85. Sève P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 2005;4:2001–7.

    Article  PubMed  Google Scholar 

  86. Sève P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 2007;13:994–9.

    Article  PubMed  Google Scholar 

  87. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study: Director’s Challenge Consortium for the molecular classification of lung adenocarcinoma. Nat Med. 2008;14(8):822–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  88. Shen Y, Tang D, Yao R, et al. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol. 2013;30(4):750.

    Article  PubMed  Google Scholar 

  89. Shintani Y, Ohta M, Hirabayashi H, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer. 2003;104:790–5.

    Article  PubMed  CAS  Google Scholar 

  90. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298–304.

    PubMed  CAS  Google Scholar 

  91. Silva J, Garcia V, Zaballos A, et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J. 2011;37:617–23.

    Article  PubMed  CAS  Google Scholar 

  92. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127:978–83.

    Article  PubMed  Google Scholar 

  93. Spano JP, Andre F, Morat L, et al. Chemokine receptor CXCR4 and early-stage non small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004;15(4):613–7.

    Article  PubMed  Google Scholar 

  94. Takise A, Kodama T, Shimosato Y, et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer. 1988;2083–2088.

    Google Scholar 

  95. Tantraworasin A, Saeteng S, Lertprasertsuke N, et al. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res. 2013;3(5):327–36.

    Article  Google Scholar 

  96. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of P53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5240–7.

    Article  PubMed  Google Scholar 

  97. Ulloa-Montoya F, Louahed J, Dizier B, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013;31:2388–95.

    Article  PubMed  CAS  Google Scholar 

  98. van Duin M, de Wit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell. 1986;44:913–23.

    Article  PubMed  Google Scholar 

  99. Vansteenkiste J, De Ruysscher D, Eberhardt WEE, et al.; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):vi89–vi98.

    Google Scholar 

  100. Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31:2396–403.

    Article  PubMed  CAS  Google Scholar 

  101. Wang SY, Ou W, Li N, et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harboring EGFR mutations: a randomized phase II study. J Clin Oncol. 2013;31(15 Suppl): abstr 7519, 462s.

    Google Scholar 

  102. Westeel V, Quoix E, Puyraveau M. et al.; Intergroupe Francophone de Cancérologie Thoracique. A randomised trial comparing preoperative to perioperative chemotherapy in early stage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer. 2013;49(12):2654–64.

    Google Scholar 

  103. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–97.

    Article  PubMed  CAS  Google Scholar 

  104. Xia Q, Zhu Z, Wang J, et al. Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non small cell lung cancer. Tumour Biol. 2012;33(5):1719–25.

    Article  PubMed  CAS  Google Scholar 

  105. Xu W, Banerji S, Davie JR, et al. Yin Yang gene expression ratio signature for lung cancer prognosis. PLoS One. 2013;8(7):e68742.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  106. Yang Y, Xie Y, Xian L. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and taxol-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. J Exp Clin Cancer Res. 2013;32:15–24.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  107. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13:48–57.

    Article  PubMed  CAS  Google Scholar 

  108. Zalcman G, Levallet G, Bergot E, et al. Evaluation of class III beta-tubulin (bTubIII) expression as a prognostic marker in patients with resectable non-small cell lung cancer (NSCLC) treated by perioperative chemotherapy (CT) in the phase III trial IFCT-0002. J Clin Oncol. 2009;27(No 15s): abstr 7526, 388s.

    Google Scholar 

  109. Zhang GB, Chen J, Wang LR, et al. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;69:1277–87.

    Article  PubMed  CAS  Google Scholar 

  110. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I non-small-cell lung cancer. Cancer. 2008;112:2765–73.

    Article  PubMed  CAS  Google Scholar 

  111. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800–8.

    Article  PubMed  CAS  Google Scholar 

  112. Zhu CQ, Pintilie M, John T, et al. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer. 2009;10:331–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, University of Torino, S. Luigi Hospital, Regione Gonzole 10, Orbassano, Torino, 10043, Italy

    Simona Carnio, Paolo Bironzo, Silvia Novello & Giorgio Vittorio Scagliotti

Authors
  1. Simona Carnio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Bironzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvia Novello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giorgio Vittorio Scagliotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giorgio Vittorio Scagliotti .

Editor information

Editors and Affiliations

  1. Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    Solange Peters

  2. Pathologie thoracique, Institut Gustave Roussy, Villejuif, France

    Benjamin Besse

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Carnio, S., Bironzo, P., Novello, S., Scagliotti, G.V. (2015). How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer?. In: Peters, S., Besse, B. (eds) New Therapeutic Strategies in Lung Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-06062-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-06062-0_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-06061-3

  • Online ISBN: 978-3-319-06062-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation